MFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
It is very uncertain whether OS‐LE changes bronchopulmonary dysplasia/chronic lung disease (incidence ‐… compared with S‐LE (very low certainty).
OS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease (sensitivity analysis) compared with S‐LE (low certainty).
It is very uncertain whether MS‐LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
All fish oil containing LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
It is very uncertain whether all alternative LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
MOFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
Bovine lung lavage surfactant extract showed no clear difference in pulmonary hemorrhage compared with modified bovine minced lung surfactant extract (moderate certainty).
The review found no eligible studies for this question.
Modified bovine minced lung surfactant extract showed no clear difference in pulmonary hemorrhage compared with porcine minced lung surfactant extract (low certainty).
The review found no eligible studies for this question.
Bovine lung lavage surfactant extract showed no clear difference in pulmonary hemorrhage compared with modified bovine minced lung surfactant extract (low certainty).
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).